Free Trial

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Rhythm Pharmaceuticals logo
$66.39 +0.62 (+0.94%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$65.86 -0.53 (-0.80%)
As of 07/7/2025 05:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Key Stats

Today's Range
$65.69
$66.83
50-Day Range
$56.79
$68.11
52-Week Range
$40.61
$69.89
Volume
821,801 shs
Average Volume
556,938 shs
Market Capitalization
$4.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.07
Consensus Rating
Buy

Company Overview

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

RYTM MarketRank™: 

Rhythm Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 233rd out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Rhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Rhythm Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rhythm Pharmaceuticals is -23.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rhythm Pharmaceuticals is -23.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rhythm Pharmaceuticals has a P/B Ratio of 189.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Rhythm Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.97% of the float of Rhythm Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Rhythm Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rhythm Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.97% of the float of Rhythm Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.
  • News Sentiment

    Rhythm Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Rhythm Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    8 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,930,651.00 in company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

  • Read more about Rhythm Pharmaceuticals' insider trading history.
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance
See More Headlines

RYTM Stock Analysis - Frequently Asked Questions

Rhythm Pharmaceuticals' stock was trading at $55.98 on January 1st, 2025. Since then, RYTM stock has increased by 18.6% and is now trading at $66.39.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.12. The business's quarterly revenue was up 25.9% compared to the same quarter last year.
Read the conference call transcript
.

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/07/2025
Today
7/08/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RYTM
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.07
High Stock Price Target
$94.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+17.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$260.60 million
Net Margins
-123.26%
Pretax Margin
-123.19%

Debt

Sales & Book Value

Annual Sales
$130.13 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
189.69

Miscellaneous

Free Float
59,740,000
Market Cap
$4.22 billion
Optionable
Optionable
Beta
2.26
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:RYTM) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners